PT  - JOURNAL ARTICLE
AU  - Francis Mccormack
AU  - Ming Yang
AU  - Elizabeth A. Morgenthien
AU  - Cindy Burg
AU  - Judit Axmann
AU  - John L. Stauffer
TI  - Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
AID  - 10.1183/13993003.congress-2020.783
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 783
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/783.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/783.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Background: Pulmonary osteoclast-like cells may contribute to lung fibrosis in IPF. BPs treat osteoporosis by inhibiting osteoclasts and reducing bone absorption.Objective: To assess the effect of BP use on lung function in pts with IPF from Phase III IPF trials.Methods: Pts randomised to pirfenidone (PFD) 2403 mg/d or placebo (PBO) in CAPACITY and ASCEND and all pts in INSPIRE (interferon γ-1b [IFNγ] and PBO) were included and grouped based on BP use during Year 1 of treatment. Changes in forced vital capacity (FVC) were analysed descriptively.Results: Overall, 899 pts received PBO, 623 pts PFD and 551 pts IFNγ. BP use was reported in 80 (8.9%), 49 (7.9%) and 70 (12.7%) pts receiving PBO, PFD and IFNγ, respectively. The mean (SD) duration of BP use was 280 (130) d, 314 (100) d and 281 (131) d for PBO, PFD and IFNγ pts, respectively. More females than males received BPs across all groups (20.2% vs. 4.6%, PBO; 24.4% vs. 2.2%, PFD; 22.9% vs. 8.8%, IFNγ, respectively). Numerically, BP users with PBO had worse FVC outcomes, with PFD had better outcomes and with IFNγ had similar outcomes vs. non-BP users (Table). PFD vs. PBO reduced lung function decline in both BP users and non-users.Conclusions: Despite small numbers, BP users with PBO had worse and those with PFD had better FVC outcomes than non-users. PFD improved outcomes in both BP users and non-users vs. PBO.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 783.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).